IDH2 and acute myeloid leukemia: With ongoing clinical studies on IDH1/2 inhibition combined with high-intensity induction regimen for newly diagnosed AML23–25, our data suggest that cladribine might be a potent combination partner for multi-agent therapy of IDH2+ AML patients.